IDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $46.00 at Mizuho

IDEAYA Biosciences (NASDAQ:IDYA) had its price objective hoisted by stock analysts at Mizuho from $44.00 to $46.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Mizuho’s target price would indicate a potential upside of 48.92% from the company’s previous close.

Several other equities analysts have also issued reports on the company. BTIG Research reiterated a “buy” rating and issued a $62.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, October 21st. Royal Bank Of Canada boosted their target price on IDEAYA Biosciences from $38.00 to $41.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 21st. JPMorgan Chase & Co. raised their price target on shares of IDEAYA Biosciences from $74.00 to $79.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a research report on Tuesday, September 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research report on Wednesday, October 8th. Fourteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, IDEAYA Biosciences has an average rating of “Moderate Buy” and an average target price of $45.50.

IDEAYA Biosciences Trading Up 2.1%

Shares of NASDAQ:IDYA opened at $30.89 on Tuesday. The firm has a 50 day moving average of $27.64 and a 200-day moving average of $23.86. IDEAYA Biosciences has a 12 month low of $13.45 and a 12 month high of $33.64. The stock has a market capitalization of $2.71 billion, a PE ratio of -16.61 and a beta of 0.14.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.33 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $1.45. The firm had revenue of $207.83 million for the quarter, compared to analyst estimates of $59.98 million. On average, research analysts predict that IDEAYA Biosciences will post -3.07 EPS for the current fiscal year.

Institutional Investors Weigh In On IDEAYA Biosciences

Several large investors have recently modified their holdings of IDYA. CWM LLC boosted its position in IDEAYA Biosciences by 325.7% during the first quarter. CWM LLC now owns 2,371 shares of the company’s stock valued at $39,000 after acquiring an additional 1,814 shares during the last quarter. Signaturefd LLC lifted its stake in shares of IDEAYA Biosciences by 374.8% in the 1st quarter. Signaturefd LLC now owns 2,877 shares of the company’s stock valued at $47,000 after purchasing an additional 2,271 shares during the period. General American Investors Co. Inc. boosted its position in shares of IDEAYA Biosciences by 116.4% during the 1st quarter. General American Investors Co. Inc. now owns 260,261 shares of the company’s stock valued at $4,263,000 after purchasing an additional 140,000 shares in the last quarter. Assetmark Inc. grew its stake in IDEAYA Biosciences by 9.9% during the first quarter. Assetmark Inc. now owns 49,750 shares of the company’s stock worth $815,000 after purchasing an additional 4,481 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in IDEAYA Biosciences by 6.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,301 shares of the company’s stock worth $349,000 after purchasing an additional 1,214 shares in the last quarter. 98.29% of the stock is currently owned by institutional investors and hedge funds.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.